Drug intelligence / Profile preview

Accelerex

Development stage: Unknown
Lead developer: Regenerex Pharma
Administration: Topical

Overview

Accelerex is a sterile, impregnated wound dressing developed and manufactured by Regenerex Pharma, Inc. It is composed of a cellulose acetate substrate coated with an ointment containing polyethylene glycols (PEG) and a specific combination of metal ions. Designed for the management of chronic, non-healing, and slow-healing wounds, Accelerex has demonstrated clinical efficacy in closing wounds that failed to respond to other standard wound care therapies. Although it contains active chemical components, it is regulated as a medical device rather than a traditional pharmaceutical drug.

Brand names: Accelerex

Beyond the preview

Go deeper on Accelerex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accelerex.

Explore the full profile